Risankizumab
- Generic Name
- Risankizumab
- Brand Names
- Skyrizi 150 Mg Dose Pack, Skyrizi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1612838-76-2
- Unique Ingredient Identifier
- 90ZX3Q3FR7
- Background
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for...
- Indication
Risankizumab is indicated to treat:
- Associated Conditions
- Moderate plaque-type psoriasis, Psoriasis, Psoriatic Arthritis, Severe Plaque Type Psoriasis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis), Severe, active Crohn´s Disease
- Associated Therapies
- -
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT03255382
- Locations
- 🇩🇪
Universitaetsklinik Heidelberg /ID# 161014, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪Universitatsklinikum Frankfurt /ID# 161036, Frankfurt, Hessen, Germany
🇩🇪Johannes Wesling Klin Minden /ID# 161015, Minden, Nordrhein-Westfalen, Germany
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT03219437
- Locations
- 🇧🇷
CETI - Centro de Estudos em Terapias Inovadoras /ID# 208593, Curitiba, Parana, Brazil
🇧🇷PUC Trials-Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR /ID# 164401, Curitiba, Parana, Brazil
🇧🇷Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu /ID# 164743, Botucatu, Sao Paulo, Brazil
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2170
- Registration Number
- NCT03047395
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center /ID# 154000, Birmingham, Alabama, United States
🇺🇸Great Lakes Research Group - Bay City /ID# 153998, Bay City, Michigan, United States
🇺🇸Oregon Medical Research Center /ID# 154003, Portland, Oregon, United States
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT03022045
- Locations
- 🇯🇵
Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan
🇯🇵Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
🇯🇵Tokyo Medical University Hosp, Shinjuku-ku, Tokyo, Japan
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000075
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT02772601
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Berlin, Germany
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT02719171
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 684
- Registration Number
- NCT02694523
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 577
- Registration Number
- NCT02684357
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 560
- Registration Number
- NCT02684370
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.